NCT02304458: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

NCT02304458
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 30 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose escalation phase (Parts A & C)
Exclusions: Patients over the age of 18; Known central nervous system (CNS) tumors or metastases
https://ClinicalTrials.gov/show/NCT02304458

Comments are closed.

Up ↑